Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

Background Molnupiravir (MOL) is an oral antiviral medication that has recently been treated
for COVID-19. Objectively We perform a prospective and observational study to elucidate the …

Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …

Background We aimed to assess the impact of antiviral drugs (fluvoxamine, remdesivir,
lopinavir/ritonavir (LPV/r), molnupiravir, andnirmatrelvir/ritonavir (NRV/r)) on health care …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among
66 007 patients with coronavirus disease 2019 in a large health care system. A possible …

Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …

ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …

Objective To estimate the effectiveness of nirmatrelvir, compared with no treatment, in
reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 …